Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 11 | Arthritis Research & Therapy

Figure 11

From: What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs

Figure 11

Additional risk of dying from an upper gastrointestinal bleed or cardiovascular event with celecoxib. For representational purposes an additional risk of 1 in about 100,000 was assumed where there was no numerically increased risk, here for either risk. GI, gastrointestinal. GI, gastrointestinal.

Back to article page